Human Anti-CTLA4 Recombinant Antibody (clone 10D1) (CAT#: HPAB-0051-YC)
The human antibody 10D1 specifically binds to human CTLA-4 or the CTLA-4 on the cell surface of normal human T cell. Herein the antibody is potentially useful for treating human diseases, infections and other conditions using these antibodies.
We specialize in custom recombinant antibody production, offering seamless execution from provided sequences to high-quality antibody deliverables, ensuring optimal yield and purity.
Figure 1 shows melanoma-specific antibody responses in animals treated with a melanoma vaccine and the anti CTLA-4 antibody 10D1.
Antibody reactivity in pooled plasma samples from treated animals was measured by flow cytometry.
Figure 2 shows the pharmacokinetic profile of the anti CTLA-4 antibody 10D1 during chronic dosing of primates.
Antibody was administered on days 0, 28, 56.84 and 140 and plasma concentrations of 10D1 were analyzed by ELISA. The mean +/-SEM of six treated animals is shown.
Figure 3 shows the pharmacokinetic profile of anti-CTLA-4 antibody 10D1 in prostate cancer patients treated with a single dose of 10D1 at day 0
Plasma concentration (ug/ml) is shown. The mean +/-SEM for 14 treated patients is shown.
Figure 4 Ligand blocking by mAb 10D1. Inhibition of recombinant B7.1 (A) and B7.2 (B) binding to CTLA-4-expressing T cells.
B7-Ig fusion proteins were incubated with huCTLA4 transfectants in the presence of varying concentrations of 10D1 F(ab)2 or isotype control F(ab)2. The mouse anti-human CTLA-4 mAb BNI-3 was also included as a positive control. B7-Ig binding was detected using goat anti-human IgG (Fc-specific)-PE probe. The cell-associated fluorescence was determined by flow cytometry, and percent inhibition of binding was determined.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Figure 5 CTLA-4 blockade with mAb 10D1 enhances Ab response to a melanoma vaccine in monkeys
Groups of six cynomolgus monkeys were given s.c. injections of 5106 SKmel-GM cells alone (arrows) or in combination with a bolus i.v. administration of mAb 10D1 (10 mg/kg). Analysis of Ab responses to SKmel-3 cells by flow cytometry (A) or ELISA (B) was determined from plasma samples taken 2 wk after each immunization. The values represent the mean SE from plasma samples, 6/group, tested at a 1/1000 dilution for flow cytometry or 1/200 for ELISA. Statistically significant differences by the Student t test are noted; p= 0.05,p=0.01,p=0.005. C, The individual animal responses by flow cytometry or ELISA (pretreatment values subtracted) at day 97.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Figure 6 Ab responses to melanoma and nonmelanoma cell lines in animals treated with melanoma vaccine and mAb 10D1.
Pooled plasma from six cynomolgus monkeys given SKmel-3-GM-CSF vaccine and mAb 10D1 (day 41) was tested for reactivity to a variety of melanoma and nonmelanoma cell lines by flow cytometry (1/1000 dilution).p 0.05human melanoma cell binding vs human nonmelanoma cells.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Figure 7 CTLA-4 blockade enhances ADCC activity in response to the melanoma vaccine.
Pooled plasma samples from vaccinated animals with or without 10D1 mAb were taken prior to immunization (Pre) or 2 wk after the second immunization (day 41). The samples were tested for ADCC activity on three melanoma cell lines at a 1/500 dilution.
Davis, T., Lonberg, N., Korman, A., Blanset, S. L., Srinivasan, M., & Graziano, R. F. (2003). Activity and Safety of CTLA-4 Blockade. J Immunol, 171, 6251-6259.
Specifications
- Immunogen
- Cells in PBS and soluble fusion protein
- Host Species
- Human
- Type
- Human IgG, κ
- Specificity
- Human CTLA4
- Species Reactivity
- Human, Monkey
- Clone
- 10D1
- Applications
- ELISA, Cyt, Block
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Target
- Alternative Names
- Cytotoxic T-Lymphocyte-Associated Protein 4; Insulin-Dependent Diabetes Mellitus 12; Celiac Disease 3; CTLA-4; CD152; Ligand And Transmembrane Spliced Cytotoxic T Lymphocyte Associated Antigen 4; Cytotoxic T Lymphocyte Associated Antigen 4 Short Spliced Form; Cytotoxic T-Lymphocyte-Associated Serine Esterase-4; Cytotoxic T-Lymphocyte-Associated Antigen 4; CD152 Isoform; CD152 Antigen; CELIAC3; IDDM12; ALPS5; GRD4; GSE; CD
- Gene ID
- 1493
- UniProt ID
- P16410
Related Resources
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone 10D1"
See other products for "CTLA4"
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-067 | Anti-Human CTLA4 Recombinant Antibody (TAB-067) | WB, FuncS, IF, Neut, ELISA, FC, IP | IgG1 - kappa |
TAB-206 | Anti-Human CTLA4 Recombinant Antibody (Ticilimumab (Tremelimumab)) | WB, IF, IP, Neut, FuncS, ELISA, FC | IgG2 |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for HPAB-0051-YC. Click the button above to contact us or submit your feedback about this product.
Popular products with customers
Application: WB, FuncS, IF, Neut, ELISA, FC, IP
Application: IP, IF, FuncS, FC, Neut, ELISA, ICC
Application: FuncS, IF, Neut, ELISA, FC, IP, IHC
Application: IF, IP, Neut, FuncS, ELISA, FC, ICC
Application: WB, FC, IP, ELISA, Neut, FuncS, IF
Application: Neut, ELISA, FuncS
Application: FC, ADCC, CDC, Inhib
Application: ELISA, IHC, FC, IP, IF, Inhib
Application: WB, ELISA, IHC, IP, SPR, FuncS
For Research Use Only. Not For Clinical Use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.